Healthy Returns: What's next for Novo Nordisk's obesity drug CagriSema Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination THIRTEEN new Ozempic like drugs are coming in the next few years as part of weight loss goldrush Daily Mail Online Trial Scorecard: REDEFINE 1 and 2 Novo Nordisk's CagriSema Study could potentially help patiend with Diabetic Neuropathy manage nerve pain. Read more on https: www.tipranks.com news company announcements novo nordisks cagrisema study a potential game changer for diabetic neuropathy VisualAbstract: Cagrilintide Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes 2 Minute Medicine